MedWatch

Analyst: Bavarian failure was no surprise

The market should not have been caught off guard by Bavarian Nordic’s failed Prostvac trial, says analyst Peter Aabo. The trial was not designed properly from the beginning.

Foto: Bavarian Nordic

When Bavarian Nordic announced the termination of the company’s Prostvac study last week, it came as a major surprise to many people.

But according to Peter Aabo, editor of Økonomisk Ugebrev Biotech and analyst for Nordic Bio Investor, the failure should not have been a huge surprise to people.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier